Results per Page:
New assay better predicts treatment for two cancers
Fred Hutch researchers develop HRDefine, a new clinical test to better serve patients with tubo-ovarian and triple-negative breast cancer
Fred Hutch researchers receive multiyear funding from the V Foundation
High-risk, high-reward research projects target triple-negative breast cancer and cancer epigenetics
Clinical trials matter: what our patients say
From brain cancer to sarcoma, Fred Hutch patients tout access to innovations, longer survival and the opportunity to help shape cancer care
Young breast cancer patient’s self-exam and self-advocacy leads to cancer diagnosis
Gillian McDonald chooses Fred Hutch for care, including participating in clinical trials that led to being selected for proton therapy